
|Articles|June 1, 2008
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
John Orwin, Genentech
S
Advertisement
ONE TO WATCH:
John Orwin, SVP, Sales and Marketing, BioOncology, Genentech
Orwin learned the landscape of onoclogy while working as senior director of oncology marketing at Alza, and then eventually as the franchise VP at J&J's Tibotec division. In 2005, he headed out to Cali to join Genentech, and was promoted the same year to head sales and marketing of its BioOncology division. And it's a good thing: Orwin was part of the commercial genius that built such heavyweights as Avastin, Herceptin, and Rituxan.
Articles in this issue
over 18 years ago
Mary Szela, Abbottover 18 years ago
Mightier Than the Swordover 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsover 18 years ago
Eric Floyd, Cephalonover 18 years ago
Nancy Phelan, Wyethover 18 years ago
Tightening the Chainover 18 years ago
Kurt Graves, Vertexover 18 years ago
Wendy Niebler, Shireover 18 years ago
Perfectly ImperfectAdvertisement
Related to this article

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than apart.

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo
2
Keeping Human Expertise at the Center of AI
3
Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout
4
Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus
5

